Kelemenis secures injunction in favour of Medicover on unfair competition grounds

Kelemenis & Co. has secured an injunction in favour of Medicover relating to the non-invasive prenatal testing (NIPT) technological platform, VERACITY. Following recent misleading and unfair statements circulating in the market, Medicover Genetics Greece secured interim judicial protection (through injunctive relief proceedings before the Court of First Instance of Athens) against a local entity that was disseminating false performance data regarding the analytical and clinical validations of VERACITY NIPT. Medicover is an international healthcare and diagnostic services provider, headquartered in Sweden and listed on Nasdaq Stockholm and operates through its two main divisions, Healthcare Services (primary care, specialist outpatient services, hospitals and clinics) and Diagnostic Services (large network of laboratories and advanced diagnostics, including genetic testing.